Prognostic value of c-Met in colorectal cancer: a meta-analysis (Q26860232)

language of work or name

1 reference

28 March 2015

1 reference

World Journal of Gastroenterology

published in

1 reference

volume

21

1 reference

page(s)

3706-10

1 reference

issue

12

1 reference

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

The Met pathway: master switch and drug target in cancer progression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Significance of micrometastases in colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

31 May 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V21.I12.3706

Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

The Sema domain of Met is necessary for receptor dimerization and activation

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4375596

bcl-2 protein expression is associated with better prognosis in colorectal cancer

28 November 2018

1 reference

12 December 2020

Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer

1 reference

12 December 2020

Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases

1 reference

12 December 2020

Clinical significance of c-met oncogene alterations in human colorectal cancer

1 reference

12 December 2020

Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer

1 reference

12 December 2020